ClinicalTrials.Veeva

Menu

Exercise Rehabilitation in Veteran Cancer Survivors

VA Office of Research and Development logo

VA Office of Research and Development

Status

Active, not recruiting

Conditions

Cancer

Treatments

Behavioral: Exercise Rehabilitation
Other: Control

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT03621813
E2870-P
HP-00081388 (Other Identifier)

Details and patient eligibility

About

Exercise rehabilitation has the potential as a non-pharmacological approach to reduce persistent neuropathic pain in Veterans with lung cancer. By examining the effects of exercise training in Veteran cancer survivors with NSCLC, there is the potential to revolutionize care for a: common, debilitating, and inadequately treated symptom in a growing population. This could lead to a larger investigation to fill critical gaps in the literature and at the same time help discover a new model of care for Veterans with chronic pain. The ultimate goal is to reduce this type of pain for the growing population of cancer survivors while simultaneously reducing the need for problematic opioid management.

Full description

Persistent or chronic neuropathic pain, either post-thoracotomy persistent pain (PTPP) or chemotherapy-induced peripheral neuropathy (CIPN) occurs in a majority of lung cancer patients. Thus, not only is this neuropathic pain widespread; there is no way to prevent its development, and long-term use of opioids for control of symptoms could result in addiction. Ultimately, PTPP and CIPN can lead to long-term suffering and disability during the post-treatment phase.(NSCLC), which represents about 85% of lung cancer cases.This is the first project of its kind and the potential impact of this research is large, because exercise training will be a prescription and the first approach for which NSCLC survivors can self-manage chronic neuropathic pain. The ultimate goal of the investigators' work is to reduce neuropathic pain for the growing population of cancer survivors while simultaneously reducing the need for problematic pharmacologic management. Therefore, results of this study have potential for high impact on symptom care because it will allow effective neuropathic pain treatment to be in full control of the Veteran, and likely restore function that is lost during the chronic pain experience.

Specific Aims:

  1. To determine the feasibility of conducting an exercise rehabilitation intervention in Veterans with NSCLC and PTPP or CIPN.
  2. To determine the effects of a VAMHCS-supervised activity rehabilitation program on chronic pain compared to delayed control.
  3. To assess changes in fitness, strength, physical function, fatigue, and quality of life (QoL) after activity-based rehabilitation compared to control period.

Enrollment

9 patients

Sex

All

Ages

60 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis with lung cancer
  • History of treatment with either thoracotomy procedure or neurotoxic chemotherapy or both
  • Completion of thoracotomy or chemotherapy > or = 6 months
  • Ability to walk on a treadmill
  • Karnofsky performance status > 70
  • Score > 1 Neuropathic Pain Scale

Exclusion criteria

  • Presence of metastatic (stage IV)
  • Life expectancy < 6 months
  • Musculoskeletal or medical conditions which preclude participation in an exercise program

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

Single Blind

9 participants in 2 patient groups

Control
Other group
Description:
Participants maintain their current activity level.
Treatment:
Other: Control
Exercise Rehabilitation
Active Comparator group
Description:
Participants will exercise 2x/week at training facilities and at home one day a week.
Treatment:
Behavioral: Exercise Rehabilitation

Trial contacts and locations

1

Loading...

Central trial contact

Alice S Ryan, PhD; Lynda C Robey

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems